INTRODUCTION
============

Postoperative nausea and vomiting (PONV) are of major concern to patients undergoing surgery under both general and regional anesthesia; ^[@B1]^ they can delay hospital discharge,^[@B2]^ and even result in overnight hospital admission to outpatient surgery.^[@B3]^ The incidence of postlaparoscopic vomiting is 35%.^[@B4],[@B5]^ Ondansetron has been shown to be effective and well tolerated in the treatment of PONV.^[@B6],[@B7]^ Ondansetron 4 mg has been shown to be the optimal dose.^[@B8]^ In the treatment of postoperative nausea and vomiting, ondansetron has also been shown to be superior to metoclopramide;^[@B9],[@B10]^ however, it has been shown to be similar to dehydrobenzoperidol (droperidol).^[@B11],[@B12]^

No previous report that compares the three drugs together for the treatment of established PONV exists in the literature. The purpose of this study is to compare the antiemetic efficacy of ondansetron versus droperidol and metoclopramide in the treatment of established PONV in patients undergoing laparoscopic surgery.

METHODS
=======

The institutional research committee approved this study, and the patients provided informed consent. American Society of Anesthesiologists (ASA) Class I and II patients undergoing laparoscopic surgery who developed postoperative nausea and vomiting were chosen. A total of 200 patients were enrolled in the study. Patients receiving pre- or intraoperative antiemetics were excluded. Also, exclusion criteria included postoperative pain scores \> 5, patients who received postoperative narcotics, pregnant females, patients with a nasogastric tube remaining postoperatively, and sedation scores \> 1. The degree of sedation was assessed as 1 = awake, 2 = drowsy, 3 = asleep.

One hundred seventy-three patients satisfied inclusion criteria. The following data were collected on all patients: age, weight, sex, history of diabetes and motion sickness, history of PONV, and type of operation, duration of surgery and anesthetic technique. The patients were divided into 3 groups. A random number was used to assign patients prospectively into one of the three treatment medications: ondansetron 4 mg, droperidol 1.25 mg, and metoclopramide 10 mg, in 2 mL solution. Fifty-seven patients received ondansetron (group O), 57 patients were given droperidol (group D), and 59 patients received metoclopramide (group M). The staff caring for these patients were blinded to the study drug received. Vital signs were recorded following each medication.

All patients were premedicated with glycopyrrolate 0.2 mg IM and diazepam 5 mg PO 45 minutes prior to the induction of anesthesia. After standard monitoring (EKG, noninvasive blood pressure, and oximetry) was applied, anesthesia was induced in the three groups with propofol 2mg/kg, fentanyl 2-3 ug/kg, and vecuronium 0.1 mg/kg. Anesthesia was then maintained by isoflurane and supplementary doses of vecuronium. The duration of the operation was recorded, and neuromuscular blockade was reversed at the end of surgery by a mixture of neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. In the recovery room and upon the complaint of nausea, vomiting, or both, assessment of the degree of nausea was made subjectively by the patient using an 11 point (0 to 10) rating score. A score of 10 corresponded to worst possible nausea, vomiting, or both. An independent blinded observer gave one of the three study medications and recorded vital signs, oxygen saturation, and the nausea scores at 10 minutes and 30 minutes following the administration of the three study groups. Also side effects, such as sedation, headache, dizziness, and agitation, were noted. Patients who continued vomiting following use of the three study drugs were given metoclopramide 10 mg as rescue antiemetics. After 2 hours, inpatients were discharged to the floor, where they were followed up for 24 hours by another independent observer; nausea score, vomiting, pain, and medications were recorded. The time for discharge of outpatients from the recovery room was also recorded.

Patient satisfaction (yes or no) was based on a questionnaire that included degree of nausea relief, side effects, and recommendations for future use.

Statistical analysis of data among the three groups was performed by the ANOVA test for nausea scores and recovery room stay and the chi-square test for rescue antiemetic use. A *P* value \< 0.05 was considered significant for both tests.

RESULTS
=======

No significant difference between the study groups existed with respect to the age, sex, weight, history of motion sickness, history of postoperative nausea and vomiting, diabetes, duration of operation and type of operation between the three groups (**[Table 1](#T1){ref-type="table"}**).

###### 

Demographic Data.

                                 Ondansetron     Droperidol      Metoclopramide
  ------------------------------ --------------- --------------- ----------------
  N                              57              57              59
  Sex: Female                    45              45              44
      Male                       11              12              15
  Weight: Female                 69.1 +/− 12.1   68.3 +/− 10.2   70.2 +/− 13.8
      Male                       87.6 +/− 18.9   85.2 +/− 17.2   89.7 +/− 19.1
  Motion Sickness                5               1               3
  PONV                           16              14              16
  Diabetic                       3               2               1
  Age                            46 +/− 17.6     44 +/− 16.2     42 +/− 18.3
  Duration of Operation          90.2 +/− 23.3   80.6 +/− 20.6   85 +/− 19.3
  Laparoscopic Cholecystectomy   30              32              33
  Laparoscopic Herniorrhaphy     6               2               4
  Laparoscopic Appendectomy      5               7               5
  Diagnostic Laparoscopy         15              16              17

As shown in **[Figure 1](#F1){ref-type="fig"}**, both ondansetron and droperidol lowered the nausea score significantly better than metoclopramide did at 10 minutes and 30 minutes (*P* \< 0.05). However, at 10 minutes, ondansetron, lowered the nausea score significantly better than droperidol did. (*P* \< 0.05).

![Nausea scores at 10 and 30 minutes versus the control score in patients who received O (Ondansetron), D (Droperidol) and M (Metoclopramide).](jsls-5-2-139-g01){#F1}

As shown in **[Figure 2](#F2){ref-type="fig"}**, out of the 57 patients who received ondansetron, 5 maintained vomiting that needed a rescue antiemetic (metoclopramide 10 mg). Out of the 57 patients who received droperidol, 6 maintained vomiting that needed a rescue antiemetic. Also, out of the 59 patients who received metoclopramide, 25 maintained nausea, vomiting, or both that needed the rescue antiemetic. A statistical difference (*P* \< 0.05) existed between the metoclopramide group and the other two groups, but no difference was noted between the ondansetron group and the droperidol group.

![Number of patients who received rescue antiemetics (Metoclopramide 10 mg IV push) versus total number of patients in the O (Ondansetron), D (Droperidol) and M (Metoclopramide) groups.](jsls-5-2-139-g02){#F2}

As shown in **[Table 2](#T2){ref-type="table"}**, 25% of patients (14/57) in the droperidol group had sedation, (sedation score = 3), but no sedation was observed in the other two groups. All other side effects (headache, dizziness, malaise, and agitation) were similar among the three groups.

###### 

Side Effects.

                       Ondansetron   Droperidol   Metoclopramide
  -------------------- ------------- ------------ ----------------
  Sedation             0             14 (25%)     0
  Headache             8 (14%)       6 (10%)      5 (8%)
  Dizziness            7 (12%)       6 (10%)      6 (10%)
  Malaise              7 (12%)       10 (17%)     6 (10%)
  Agitation            2 (4%)        3 (5%)       3 (5%)
  Extrapyramidal Spt   0             0            0

Also, the average time for discharge from the recovery room was 170 minutes +/− 30 for group O, 250+/− 55 for group D, and 210+/− 50 for group M. A significant difference existed between the three groups (*P* \< 0.05). Patient satisfaction was best with ondansetron 82%, metoclopramide 65%, and droperidol 59%.

DISCUSSION
==========

Postoperative nausea and vomiting are multifactorial in origin. Patient-controlled factors like age, sex, obesity, history of motion sickness, history of previous PONV and diabetes exist. Surgical factors like type of surgery, duration of surgery, type of anesthesia, along with postoperative pain or analgesia (narcotics) contribute to its etiology.^[@B1]^ In this study, however, the treatment groups were similar with regards to patient demographics, surgical procedure, anesthetics administered, and analgesics Therefore, the response to the different treatment drugs can be attributed to the antiemetic drug administered.

The antiemetic mechanism can be either central or peripheral. Drugs used for the treatment of PONV are usually antihistaminics, anticholinergics, dopamine receptor antagonists, and 5HT3 antagonists.^[@B1]^ The present study is the only report that compares the three drugs ondansetron, droperidol, and metoclopramide for the treatment of PONV. Our results show that both ondansetron 4 mg and droperidol 1.25 mg are more effective than metoclopramide 10 mg in the treatment of established postoperative nausea and vomiting in patients undergoing laparoscopic surgery. Although the nausea score at 30 minutes shows no significant difference between group O and group D, the nausea score analysis at 10 minutes shows that ondansetron is better than droperidol. In addition, droperidol 1.25 mg caused a 25% incidence of sedation and a longer stay in the recovery room for outpatient surgery.

In conclusion, we have shown that ondansetron 4 mg and droperidol 1.25 mg are more effective than 10 mg metoclopramide in the treatment of established PONV in adult patients undergoing laparoscopic surgery. However, droperidol was significantly less effective at 10 minutes than ondansetron is at decreasing nausea scores. Also, droperidol was followed by sedation associated with a prolonged recovery room stay.

Therefore, the use of ondansetron is recommended in outpatient surgery.
